LLYELI LILLY & Co
Pharmaceutical Preparations
- Revenue
- $65.2B
- 45% YoY
- Operating margin
- —
- EBITDA
- —
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $37.6B net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear81% of net incomeCash flow under 80% of net income
- Dilutive SBCClear1% of revenueOver 10% of revenue
- Payouts exceed cash flowClear56% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear7% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $28.3B | $28.5B | $34.1B | $45.0B | $65.2B | 45% |
| Net income | $5.6B | $6.2B | $5.2B | $10.6B | $20.6B | 95% |
| Operating cash flow | $7.4B | $7.6B | $4.2B | $8.8B | $16.8B | 91% |
| Stock-based comp | $343M | $371M | $629M | $646M | $626M | 3.1% |
| Buybacks | $1.3B | $1.5B | $750M | $2.5B | $4.1B | 64% |
| Dividends | $3.1B | $3.5B | $4.1B | $4.7B | $5.4B | 15% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.